Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
MgffswARrtTWPUgC
